Introduction
============

Hepatitis B virus (HBV) infection represents a global health problem with \~50 million patients suffering from chronic hepatitis B (CHB) infection worldwide ([@b1-etm-0-0-4361]). Each year \~1 million patients die due to cirrhosis and hepatocellular liver failure as a result of HBV infection ([@b2-etm-0-0-4361]). Acute-on-chronic liver failure (ACLF) is an acute deterioration of liver function in patients with chronic liver disease, which manifests as coagulopathy and severe jaundice, and is typically complicated within 4 weeks by ascites and/or encephalopathy ([@b3-etm-0-0-4361]). ACLF is characterized by its rapid progression and high mortality of 50--90% ([@b3-etm-0-0-4361]).

Interleukin (IL)-1 serves a crucial role in the immune response and inflammation and IL-1 receptor antagonist (ra), the naturally-occurring anti-inflammatory antagonist of IL-1, has also been established to be associated with various inflammatory and autoimmune disorders ([@b4-etm-0-0-4361]). An imbalance of IL-1ra and IL-1 results in the progression of various diseases ([@b5-etm-0-0-4361]). Although the complete pathophysiology of ACLF is not yet fully understood, uncontrolled hepatic immunoactivation, in particular the disorder of cytokines is thought to be the primary underlying pathological mechanism ([@b6-etm-0-0-4361]). In China, \>96% of ACLF cases are associated with HBV ([@b7-etm-0-0-4361]). The underlying mechanisms of HBV-induced immunopathological damage leading to liver failure remain unclear; therefore, investigating the changes in cytokine expression patterns in patients with HB-ACLF may facilitate the understanding of this underlying pathogenesis.

The present study was designed to analyze whether IL-1ra is associated with the progression of HBV-related ACLF (HB-ACLF). Healthy individuals and patients with acute HBV (AHB) or CHB were selected as controls and for comparison. Serum concentrations of IL-1ra and other cytokines \[IL-1β, IL-4, IL-6, interferon (IFN)-γ, IL-10, and tumor necrosis factor (TNF)-α\] were measured. The association between serum IL-1ra and the prognosis of HB-ACLF was also assessed, as well as the association of IL-1ra with other cytokines *in vitro*.

Materials and methods
=====================

### Study subjects

A total of 31 patients with ACLF, 28 patients with AHB, and 31 patients with CHB who were admitted to the Infectious Disease Hospital of Fujian Medical University (Fuzhou, China) between November 2013 and January 2015 were enrolled in the present study. Additionally, 15 healthy volunteers were enrolled as healthy controls (HC). The patients were aged between 19 and 48 years (median=28) and consisted of 86 males and 19 females. Patient demographics are displayed in [Table I](#tI-etm-0-0-4361){ref-type="table"} and were well balanced across groups. None of the patients had received antiviral treatment or plasma exchange in the 6 months prior to the study. A total of 10 ml blood was harvested from each patient with HB-ACLF upon admission. Patients with HB-ACLF received comprehensive liver-protecting treatment with human albumin, L-ornithine L-aspartate injection and polyene phosphatidylcholine injection on the day of admission prior to blood sampling and did not receive any treatement prior to admission. AHB and CHB were diagnosed in accordance with the diagnostic criteria as previously described ([@b8-etm-0-0-4361]). Briefly, the criteria for AHB was HBV surface antigen (HBsAg)-negative conversion within 6 months of the initial onset of symptoms resulting from HBV infection. The diagnosis of CHB was based on a history of serum HBsAg positivity \>6 months, serum alanine aminotransferase (ALT) levels greater than the upper limit of the normal level, serum total bilirubin (TBIL) \<10 times the normal level (171 µmol/l), and prothrombin time activity (PTA) \>40%. HB-ACLF was diagnosed according to the criteria recommended by The 19^th^ Conference of the Asian Pacific Association for the Study of the Liver in 2009 ([@b9-etm-0-0-4361]).

Patients with any of the following conditions were excluded from the present study: Concurrent hepatitis A, C, D, or E virus, human immunodeficiency virus (HIV) infections, other liver diseases (such as Wilson\'s disease, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease), bacterial infection, diabetes mellitus or tumor.

The HC group was recruited from staff and students at the Infectious Disease Hospital of Fujian Medical University. The Model for End-stage Liver Disease (MELD) score was calculated using the following formula: 3.8 × log \[bilirubin (mg/dl)\] + 11.2 × log (INR) + 9.6 × log \[creatinine (mg/dl)\] + 6.4 ([@b10-etm-0-0-4361]).

### Ethical considerations

The ethics committee of the Infectious Disease Hospital of Fujian Medical University approved the present study. Written informed consent was obtained from all subjects.

### Serological and HBV DNA assays

Non-heparinized arterial blood was centrifuged at 500 × g for 5 min at 20°C and stored at −80°C. Serum levels of HBsAg, hepatitis B virus surface antibody (anti-HBs), hepatitis B virus e antigen (HBeAg), hepatitis B virus e antibody (anti-HBe), hepatitis B virus core antibody (anti-HBc), anti-hepatitis A virus, anti-hepatitis C virus, anti-hepatitis D virus, anti-hepatitis E virus, and anti-HIV antibodies were tested using AxSYMMEI kits according to the manufacturer\'s protocol (Abbott Laboratories, Abbott Park, IL, USA). The HBV DNA level was measured using a quantitative polymerase chain reaction (PCR) kit (cat. no. 041611; Triplex International Biosciences Co., Ltd., Fuzhou, China) with a detection limit \<420 IU/ml. HBV DNA was extracted using silica-based technology as described by Boom *et al* ([@b11-etm-0-0-4361]). PCR was then performed on a STRATAGENE Mx3000P (Stratagene; Agilent Technologies, Inc., Santa Clara, CA, USA) instrument. Positive quality control, weak-positive quality control, negative quality control and 5 quantitative reference products (1.0×10^3^, 1.0×10^4^, 1.0×10^5^, 1.0×10^6^ and 1.0×10^7^ IU/ml, respectively) were set. Three replicates were performed for each sample. The total PCR reaction volume was 50 µl comprised of the following: 29 µl PCR solution (containing primers, probe, dN(U) TP and other buffers), 1 µl Taq DNA polymerase and 20 µl purified DNA. The amplification was conducted as follows: Initial activation step at 37°C for 2 min, initial hot start denaturation at 94°C for 2 min, followed by 40 cycles of denaturation at 94°C for 15 sec and annealing and extension at 55°C for 45 sec. The fluorescence was measured at the extension stage of each cycle. The quantification of DNA was calculated using the 2^−∆∆Cq^ method ([@b12-etm-0-0-4361]). The quantitative analyses were performed by using STRATAGENE Mx3000P analysis software version 1.0 (Stratagene; Agilent) following the manufacturer\'s protocol. The sequences of the primers used were not provided with the kit.

### Measurements of serum cytokine concentrations

Serum concentrations of cytokines (IL-1ra, IL-1β, IL-4, IL-6, IFN-γ, IL-10, and TNF-α) were measured using a Q-Plex multiplex array (cat. no. 104750GR; Quansys Biosciences, Logan, UT, USA) on a Q-View Imager (Quansys Biosciences) according to the manufacturer\'s protocol.

### Incubation of peripheral blood mononuclear cells (PBMCs) with IL-1ra in vitro

PBMCs were isolated from the heparinized blood of 31 patients with ACLF via centrifugation at 800 × g at 20°C for 20 min using Ficoll Lymphoprep (Axis-Shield Diagnostics Ltd., Dundee, UK). Mononuclear cell bands were subsequently harvested using a Pasteur pipette and resuspended in PBS. Cells were centrifuged again at 650 × g at 20°C for 10 min, resuspended in PBS and centrifuged for a final time at 500 × g at 20°C for 10 min. Cells were resuspended in RPMI 1640 (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.). A total of 1×10^6^ cells in 200 µl RPMI were subsequently seeded into 96-well plates and stimulated with PBS, lipopolysaccharide (LPS; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), LPS + 125 ng/ml recombinant human (rh) IL-1ra (ProSpec, East Brunswick, NJ, USA), LPS + 250 ng/ml rhIL-1ra, or LPS + 500 ng/ml rhIL-1ra. Cells were incubated for 24 h at 37°C in at atmosphere containing 5% CO~2~ with 75% humidity, following which supernatants were collected and stored at −80°C for uniform testing. The concentrations of IL-1β, IL-4, IL-6, IL-10, IFN-γ, and TNF-α were measured as described above.

### Statistical analysis

All data were analyzed using SPSS 13.0 (SPSS, Inc., Chicago, IL, USA). Data are expressed as the medians (interquartile range) or mean ± standard deviation. Continuous variables were analyzed using the Kruskal-Wallis H-test, or Mann-Whitney U-test. Fisher\'s exact test was used for interclass comparisons of categorical variables. Statistical associations between variables were assessed using the Spearman rank order correlation coefficient. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Serum cytokine concentrations

Comparisons of serum cytokine concentrations in each group are presented in [Table II](#tII-etm-0-0-4361){ref-type="table"}. The serum levels of IL-1ra in the HB-ACLF group were 186.46 (350.22) pg/ml, which were significantly higher compared with the AHB (P\<0.01), CHB (P\<0.001), and HC (P\<0.001) groups. Serum concentrations of IL-1β \[62 (66.5) pg/ml\], IL-6 \[234.26 (210.91) pg/ml\], and TNF-α \[30.97 (26.77) pg/ml\] were also found to be significantly higher in the HB-ACLF group compared with all other groups (all P\<0.01). There were no significant differences in the serum concentrations of IL-4, IL-10, or IFN-γ between the ACLF and AHB groups. Compared with the CHB group, the mean levels of IL-1ra, IL-1β and IL-6TNF-α in the HB-ACLF group, and the levels of IL-1ra and IL-6 in the AHB group were significantly higher (all P\<0.01). The ratio of IL-1ra to IL-1β was significantly lower in the HB-ACLF group at 2.96 (2.54) compared with in the AHB group at 4.54 (3.29; P=0.048; [Fig. 1](#f1-etm-0-0-4361){ref-type="fig"}).

### Associations between IL-1ra and clinical outcomes

A total of 31 patients with HB-ACLF were subdivided into surviving (n=19) and deceased (n=12) groups ([Table III](#tIII-etm-0-0-4361){ref-type="table"}). Serum concentrations of IL-1ra were significantly lower in the deceased ACLF group at 166.8 (71.53) pg/ml compared with the surviving group at 317.27 (92.08) pg/ml (P=0.02). The ratio of IL-1ra to IL-1β was also lower in the deceased group \[2.11 (1.51)\] compared with the surviving group \[4.06 (3.58); P=0.007\]. Furthermore, the deceased group were found to have significantly higher levels of IL-6 (P=0.032), IFN-γ (P=0.01), and TNF-α (P=0.039), and lower levels of IL-10 (P=0.028) compared with the surviving group However, no significant differences were observed in IL-4 and IL-1β levels between the two groups ([Fig. 2](#f2-etm-0-0-4361){ref-type="fig"}).

### Associations between IL-1ra and severity of HB-ACLF

The results of the present study revealed an inverse relationship between the MELD score and serum levels of IL-1ra (r=−0.818; P\<0.001), IL-1ra/IL-1β (r=−0.634; P\<0.001), and IL-10 (r=−0.861; P\<0.001). Conversely, MELD scores were positively associated with serum levels of IL-6 (r=0.086; P\<0.001), IFN-γ (r=0.954; P\<0.001), and TNF-α (r=0.833; P\<0.001; [Fig. 3](#f3-etm-0-0-4361){ref-type="fig"}).

### Associations between IL-1ra and HBV DNA and liver function

IL-1ra was demonstrated to be negatively associated with TBIL (r=−0.506; P=0.0004) and positively associated with PTA (r=0.475; P=0.007). However, IL-1ra was not associated with ALT, aspartate aminotransferase, ALB, or HBV DNA ([Fig. 4](#f4-etm-0-0-4361){ref-type="fig"}).

### Associations between IL-1ra and other cytokines

Serum IL-1ra levels were positively correlated (n=105) with serum levels of IL-1β (r=0.766; P\<0.001), IL-6 (r=0.506; P\<0.001), IL-10 (r=0.40; P\<0.001), and TNF-α (r=0.277; P=0.004), but not with levels of IFN-γ or IL-4 ([Fig. 5](#f5-etm-0-0-4361){ref-type="fig"}).

### Inhibition of cytokine secretion in LPS-stimulated PBMCs by rhIL-1ra

The concentrations of cytokines secreted by PBMCs from patients with HB-ACLF are presented in [Fig. 6](#f6-etm-0-0-4361){ref-type="fig"}. A significant increase in the levels of 6 cytokines was detected following LPS stimulation of PBMCs compared with the PBS group (all P\<0.001). A significant decrease was observed in levels of IL-1β (P=0.001), IL-6 (P\<0.001), IL-10 (P=0.018), IFN-γ (P=0.036), and TNF-α (P=0.03) following the addition of rhIL-1ra compared with the LPS group. As expected, the inhibitory effects of IL-1ra occurred in a dose-dependent manner. However, no significant differences in IL-4 levels were observed among groups. This outcome was consistent with the serum findings ([Fig. 6](#f6-etm-0-0-4361){ref-type="fig"}).

Discussion
==========

The results of the present study demonstrated that concentrations of four cytokines (IL-1ra, IL-1β, IL-6 and TNF-α) were increased significantly in patients with HB-ALCF compared with the AHB and CHB groups. However, the ratio of IL-1ra to IL-1β was lower in the HB-ACLF group compared with the AHB group. Notably, serum IL-1ra concentration was negatively associated with MELD score. IL-1ra concentrations and the ratio of IL-1ra/IL-1β in the deceased group were significantly lower than that in the surviving group. *In vitro*, cytokine secretion by PBMCs was significantly inhibited in a dose-dependent manner by rhIL-1ra treatment. This suggests that IL-1ra serves an important role in the development of liver inflammation, which is relatively reduced in patients with HB-ACLF and inversely associated with disease severity. The results of the present study are in accordance with the observation of Hope *et al* ([@b13-etm-0-0-4361]) that IL-1Ra is associated with disease severity in mental illness.

Previous studies have established that an inflammatory environment is a key determinant in the progression of liver failure ([@b14-etm-0-0-4361],[@b15-etm-0-0-4361]). The pro-inflammatory cytokine IL-1 has a key role in regulating inflammatory and immune responses ([@b16-etm-0-0-4361],[@b17-etm-0-0-4361]). IL-1ra, a natural IL-1 antagonist acts via competitive inhibition without triggering a signaling cascade to reduce inflammation ([@b18-etm-0-0-4361]). Imbalances between IL-1 and IL-1ra are observed in many inflammatory disorders ([@b5-etm-0-0-4361],[@b19-etm-0-0-4361],[@b20-etm-0-0-4361]), which is consistent with the results of the present study. Although serum IL-1ra concentration was higher in patients with HB-ACLF compared with patients with AHB, IL-1ra/IL-1β was lower. This suggests that endogenous IL-1ra was insufficient to antagonize the action of IL-1, resulting in a cascade of inflammation, which led to liver damage.

IL-1ra is expressed by various immune cells including monocytes, macrophages, and T cells, as well as by nonimmune cells ([@b13-etm-0-0-4361],[@b21-etm-0-0-4361]). It has an anti-inflammatory effect, which is achieved via various pathways. When IL-1β induces the dimerization of IL-1 receptor accessory protein (IL-1RAcP) with IL-1-receptor type 1 (IL-1R1) to produce and release inflammatory cytokines, IL-1ra is able to prevent the recruitment of IL-1RAcP to regulate the inflammatory response ([@b5-etm-0-0-4361]). IL-1ra also blocks the biological activity of IL-1 by competitively binding to the IL-1 type I receptor (IL-1RI), which is expressed by various tissues ([@b4-etm-0-0-4361]). Additionally, it has been reported that IL-1ra is able to control the activation and migration of dendritic cells, thereby affecting local immune responses ([@b22-etm-0-0-4361]). IL-1ra also has anti-apoptotic roles in both acute and chronic inflammation, and is able to promote hepatocyte proliferation ([@b6-etm-0-0-4361]). A previous study suggested a potential role for IL-1ra in hepatocyte proliferation via promoting cell cycle transition from G1 to S phase ([@b23-etm-0-0-4361]). rhIL-1ra has been shown to have therapeutic effects in various inflammatory and autoimmune conditions mediated by the pathophysiological effects of IL-1 ([@b24-etm-0-0-4361]--[@b29-etm-0-0-4361]) in a dose-dependent manner.

In order to further investigate the role of IL-1ra in HB-ACLF, PBMCs were isolated from patients with HB-ACLF and incubated with various concentration of rhIL-1ra *in vitro*. The results revealed that rhIL-1ra induced the expression of anti-inflammatory cytokines, such as IL-10 and IL-4, and also reduced the production of pro-inflammatory cytokines, such as IFN-γ, IL-1, and IL-6. Furthermore, this inhibitory effect occurred in a dose-dependent manner. These results were in accordance with the observation of Petrasek *et al* ([@b30-etm-0-0-4361]) that administration of IL-1Ra dose-dependently ameliorated alcohol-induced liver steatosis and decreased levels of IL-1, TNF-α and MCP-1 in the serum of wild type mice injected with 1.5, 10, or 25 mg/kg IL-1Ra daily.

Notably, serum concentrations of IL-1ra appeared to be correlated with gender. The findings of the present study demonstrated that serum levels of IL-1ra in female patients with ACLF were significantly higher than those in males. These observations are consistent with those of Stosić-Grujicić ([@b31-etm-0-0-4361]), who reported that peripheral monocytes obtained from women during the menstrual cycle produced 5--10 times more IL-1ra than cells from men. A possible explanation for this difference may be a difference in IL-1RN between female and male patients. Tountas *et al* ([@b32-etm-0-0-4361]) reported that the IL1RNVNTR A2 allele has been associated with reduced levels of IL-1ra.

There were several limitations to the present study. Patients with moderate CHB were not distinguished from those with severe CHB, as the latter has been associated with a relatively better prognosis than ACLF, but is much more severe than that of moderate CHB ([@b26-etm-0-0-4361],[@b33-etm-0-0-4361]). Furthermore, markers were only measured at one time point for some patients who received plasma exchange, which may have influenced cytokine measurements. Markers in the liver were not characterized due to the poor condition of patients with HB-ACLF, making them unsuitable for liver biopsy.

Collectively, although serum levels of IL-1ra in patients with HB-ACLF increased significantly due to the activation of IL-1, the ratio of IL-1ra/IL-1β was lower in the HB-ACLF group compared with the AHB group. This suggests that IL-1 signaling in the liver is subject to tight endogenous control, and endogenous IL-1ra is insufficient to neutralize the effects of IL-1 in patients with HB-ACLF. Additionally, lower IL-1ra concentrations were demonstrated to be associated with increased disease severity and poor survival in patients with HB-ACLF. PBMCs from patients with HB-ACLF treated with IL-1ra are able to regulate immune disorders. The present study indicates that immune activation has a role in the core pathological mechanisms of HB-ACLF. The underlying mechanisms, including the potential impact of IL-1ra on HB-ACLF severity and the clinical significance of immune suppression, remain to be elucidated and require further evaluation in larger studies.
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![Associations between serum IL-1ra and clinical outcomes. Horizontal bars indicate the median values in each group. P-values indicate the significance between groups as determined via a Mann-Whitney U Test. IL, interleukin; ra, receptor antagonist; HB-ACLF, hepatitis B-related acute-on-chronic liver failure; survivors, surviving patients in HB-ACLF group; Non-survivors, deceased patients in HB-ACLF group; TNF, tumor necrosis factor; IFN, interferon.](etm-13-06-2867-g01){#f2-etm-0-0-4361}

![Correlation between serum cytokine levels and MELD score. The serum levels of IL-1ra, IL-1ra/IL-1β and IL-10 were negatively associated with MELD score (all P\<0.001). The serum levels of IL-6, IFN-γ and TNF-α were positively associated with MELD score (all P\<0.001). There was no correlation between serum levels of IL-1β or IL-4 and MELD score. MELD, Model for End-stage Liver Disease; IL, interleukin; ra, receptor antagonist; IFN, interferon; TNF, tumor necrosis factor.](etm-13-06-2867-g02){#f3-etm-0-0-4361}

![Spearman correlation coefficient between IL-1ra and (A) HBV DNA or (B-F) liver function measures. IL-1ra was negatively associated with TBIL (P=0.0004) and positively associated with PTA (P=0.007). IL, interleukin; ra, receptor antagonist; HBV, hepatitis B virus; TBIL, total bilirubin; PTA, prothrombin time activity; ALB, albumin; ALT, alanine aminotransferase; AST, glutamic oxalacetic transaminase.](etm-13-06-2867-g03){#f4-etm-0-0-4361}

![Association between IL-1ra and other cytokines. Serum IL-1ra levels were correlated with serum levels of IL-1β (P\<0.001), IL-6 (P\<0.001), IL-10 (P\<0.001) and TNF-α (P=0.004). IL, interleukin; ra, receptor antagonist; TNF, tumor necrosis factor; IFN, interferon.](etm-13-06-2867-g04){#f5-etm-0-0-4361}

![Inhibition of cytokine secretion in LPS-stimulated PBMCs by rhIL-1ra. LPS, lipopolysaccharide; PBMCs, peripheral blood mononuclear cells; rh, human recombinant; IL, interleukin; ra, receptor antagonist; low, LPS + 125 ng/ml rhIL-1ra; middle, LPS + 250 ng/ml rhIL-1ra; high, LPS + 500 ng/ml rhIL-1ra; IFN, interferon; TNF, tumor necrosis factor.](etm-13-06-2867-g05){#f6-etm-0-0-4361}

###### 

Clinical characteristics between groups.

  Characteristic              HB-ACLF (n=31)            AHB (n=28)               CHB (n=31)             HC (n=15)             P-value
  --------------------------- ------------------------- ------------------------ ---------------------- --------------------- -------------
  Gender (M/F)                25/6                      23/5                     26/5                   12/3                  0.985
  Age (years)                 36 (23--46)               33 (19--45)              36 (20--48)            33 (19--45)           0.103
  HBeAg (Pos/Neg)             24/7                      22/6                     23/8                   --                    0.152
  HBVDNA (log~10~copies/ml)   6.45 (2.66--8)            5.37 (3.08--7.95)        7.34 (4.68--9.95)      --                    **\<0.001**
  Albumin (g/l)               30 (18--39)               37 (30--42)              35 (29--42)            38 (35--42)           **\<0.001**
  Bilirubin (µM)              372.30 (216.80--702.90)   106.03 (29.60--311.00)   33.90 (8.09--241.00)   13.90 (7.00--27.03)   **\<0.001**
  ALT (U/l)                   571 (50--2554)            570 (105--2013)          230 (35--1202)         13 (7--32)            **\<0.001**
  PTA (%)                     28 (12--40)               81 (50--118)             80 (54--120)           99 (80--124)          **\<0.001**

Quantitative variables are presented as the median (range). Categorical variables are presented as counts. Bold text indicates a statistically significant difference. HB-ACLF, hepatitis B-related acute-on-chronic liver failure; AHB, acute hepatitis B; CHB, chronic hepatitis B; HC, healthy control; Pos, positive; Neg, negative; ALT, alanine aminotransferase; PTA, prothrombin time activity.

###### 

Comparisons of serum cytokines in the four groups.

  Cytokine   HB-ACLF                                                                                                       AHB                                                                                                          CHB                                                           HC
  ---------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------- ---------------
  IL-1ra     186.46 (350.22)^[a](#tfn3-etm-0-0-4361){ref-type="table-fn"}--[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^   143.69 (90.79)^[b](#tfn4-etm-0-0-4361){ref-type="table-fn"},[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^    70.47 (45.40)^[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^   33.82 (26.99)
  IL-1β      62.00 (66.50)^[a](#tfn3-etm-0-0-4361){ref-type="table-fn"}--[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^     36.08 (41.44)^[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^                                                  31.85 (18.77)^[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^   10.40 (7.06)
  IL-4       4.11 (1.26)                                                                                                   3.47 (2.18)                                                                                                  3.2 (0.81)                                                    3.88 (2.33)
  IL-6       234.26 (210.91)^[a](#tfn3-etm-0-0-4361){ref-type="table-fn"}--[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^   158.51 (147.19)^[b](#tfn4-etm-0-0-4361){ref-type="table-fn"},[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^   20.34 (39.05)^[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^   9.23 (1.31)
  IFN-γ      46.12 (23.58)^[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^                                                   41.35 (25.71)                                                                                                36.49 (39.15)                                                 26.55 (29.03)
  IL-10      8.18 (2.92)^[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^                                                     8.23 (3.48)^[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^                                                    8.78 (3.40)^[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^     5.52 (3.12)
  TNF-α      30.97 (26.77)^[a](#tfn3-etm-0-0-4361){ref-type="table-fn"}--[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^     21.11 (7.03)^[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^                                                   22.88 (6.63)^[c](#tfn5-etm-0-0-4361){ref-type="table-fn"}^    10.65 (5.79)

Datas are presented as median (interquartile range).

P\<0.01 vs. AHB group

P\<0.01 vs. CHB group

P\<0.001 vs. HC group. HB-ACLF, hepatitis B-related acute-on-chronic liver failure; AHB, acute hepatitis B; CHB, chronic hepatitis B; HC, healthy control; IL, interleukin; ra, receptor antagonist; IFN, interferon; TNF, tumor necrosis factor.

###### 

Clinical characteristics in survivor and non-survivor patients with HB-ACLF.

  Group          Gender (M/F)   Age (y)   HBeAg (+/−)   HBV-DNA Log(copies/ml)   ALB (g/l)   TBIL (µM)   ALT (U/l)   PTA (%)     ALPT (Y/N)   AT (Y/N)
  -------------- -------------- --------- ------------- ------------------------ ----------- ----------- ----------- ----------- ------------ ----------
  Survivor       15/4           35 (8)    15/4          6.1 (3)                  28 (9)      465 (194)   562 (719)   24 (14)     16/3         19/0
  Non-survivor   9/3            37 (7)    10/2          6.6 (1.6)                32 (4)      299 (55)    785 (880)   34 (10)     10/2         12/0
  P-value        0.763          0.745     0.531         0.700                    **0.029**   **0.021**   0.330       **0.004**   0.984        --

Quantitative variables are presented as median (interquartile range). Categorical variables are presented as counts. Bold text indicated a statistically significant difference. HB-ACLF, hepatitis B-related acute-on-chronic liver failure; M, male; F, female; y, years; HBeAg, hepatitis B virus e antigen; HBV, hepatitis B virus; ALT, alanine aminotransferase; +, positive; -, negative; ALB, albumin; TBIL, total bilirubin; PTA, prothrombin time activity; Y, yes; N, No; ALPT, artificial liver support therapies; AT, antiviral therapies.
